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Abstract 
Purpose: To report the postoperative courses of 2 patients with Fuchs heterochromic 
iridocyclitis (FHI) and the concentrations of various cytokines, chemokines and growth 
factors in vitreous fluid samples to obtain insights into pathobiochemical aspects.  
Subjects: The patients were a 27- and a 47-year-old woman. Phacoemulsification and 
aspiration, intraocular lens (IOL) implantation, and pars plana vitrectomy were performed 
to treat their cataracts and vitreous opacities. During their early postoperative periods, 
inflammatory cells precipitated on the IOL and intraocular pressure was increased in 
both patients.  
Methods: At the time of surgery, undiluted vitreous fluid specimens were collected. The 
concentrations of multiple cytokines, chemokines and growth factors were measured by 
a bead array immunodetection system.  
Results: The levels of interleukin-1ra, -5, -6, -8, -10 and -13, interferon-inducible 10-kDa 
protein, monocyte chemoattractant protein 1, macrophage inflammatory protein 1β, and 
regulated upon activation, normal T-cell expressed and secreted (RANTES) were 
significantly elevated in vitreous fluid in both patients.  
Conclusion: Although the postoperative course was generally favorable in patients with 
FHI, steroid instillation was necessary for a few months postoperatively, as precipitates 
easily formed on the IOL surface and elevated intraocular pressure. The profiles of 
intravitreal concentrations of cytokines, chemokines and growth factors may 
characterize postoperative inflammatory reactions. 
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Introduction 
Fuchs heterochromic iridocyclitis (FHI) is a kind of uveitis characterized by 3 major 
symptoms: heterochromia iridis, iridocyclitis and cataract [1]. Visual acuity is reportedly 
reduced in 96% of all FHI patients due to cataracts or vitreous opacity [2]. Although a 
number of independent reports regarding cataract surgery [3–7] and vitrectomy [8–10] 
procedures have been presented, relatively few have described combined vitrectomy and 
cataract surgery [11]. The usefulness of combination surgery is expected, as FHI 
reportedly causes not only cataracts but also vitreous opacity in 66–84% of the patients [2, 
12]. 
As for intraocular cytokines, chemokines and growth factors that may modify 
inflammatory cell reactions and/or complications such as cataract, previous data reported 
by several investigators have proven somewhat ambiguous. Some researchers have 
reported that interferon (IFN)-γ [13], interleukin (IL)-2 [14], and IL-10 [14] are increased 
in aqueous humor, and IL-2 is increased in vitreous fluid [15] in patients with FHI. 
Conversely, Curnow et al. [16] reported that IL-2, -12 and -13 were significantly 
decreased and IL-6 was no different in FHI aqueous humor compared to in 
noninflammatory aqueous humor. Excluding the multiplex bead array analysis by 
Curnow et al. [16] using aqueous humors and Banerjee et al. [17] using vitreous fluids, 
most previous studies have employed enzyme-linked immunosorbent assay (ELISA) with 
limited numbers of target proteins [12–15], so the exact profiles of cytokines, chemokines 
and growth factors distributed in vitreous fluid from patients with FHI have remained 
unclear. 
We report herein 2 patients who underwent combined vitrectomy and cataract surgery 
for cataract and vitreous opacity associated with FHI. The concentrations of 27 different 
cytokines, chemokines and growth factors in vitreous fluid samples collected during 
vitrectomy were determined using a multiplex bead array immunodetection system (Bio-
Plex; Bio-Rad, Hercules, Calif., USA) to obtain some insights into the pathobiochemical 
aspects of FHI. 
Subjects and Methods 
Subjects 
Two female patients with FHI were referred to our clinic at the Hirosaki University Hospital in 2006, 
complaining of decreased visual acuity in the left eye, which showed cataracts and vitreous opacity. We 
performed combined phacoemulsification (PEA), pars plana vitrectomy (PPV) and intraocular lens 
(IOL) implantation in both patients, because vitreous opacity was gradually increased although an active 
inflammatory reaction was not clinically detected in either patient. After PEA, 3 scleral ports were 
prepared for PPV. A 0.3-ml sample of undiluted vitreous fluid was collected before starting the PPV 
procedures with a 20-gauge cutter connected to a 2.0-ml syringe. Vitreous fluid was aspirated into the 
syringe by manually added suction pressure with a cutting rate of 400 cpm. The collected vitreous fluid 
was frozen and kept at –80°C until bead array assay. Informed consent was obtained from each patient 
before surgery. This study was approved by the institutional committee of ethics and followed the tenets 
of the Declaration of Helsinki. Written and signed statements of the patients’ informed consents were 
obtained to report their personal details and photographs. 
Methods 
The concentrations of 27 different cytokines, chemokines and growth factors in the vitreous fluid 
samples were simultaneously determined using a multiplex bead array immunodetection system (Bio- 
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Plex; Bio-Lad) in accordance with the protocol set by the manufacturer. The immunodetection system 
contains bead-conjugated antibodies raised against 27 different cytokines, chemokines and growth 
factors as follows: interleukin-1β (IL-1β), IL-1 receptor antagonist (IL-1ra), IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-8 (chemokine C-X-C motif ligand (CXCL) 8), IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, eotaxin 
(chemokine C-C motif ligand (CCL) 11), basic fibroblast growth factor (b-FGF), granulocyte-colony 
stimulating factor (G-CSF), granulocyte/macrophage-colony stimulating factor (GM-CSF), interferon 
(IFN)-γ, INF-inducible 10-kDa protein (IP-10, CXCL10), monocyte chemoattractant protein-1 (MCP-1, 
CCL2), macrophage inflammatory protein-1 (MIP-1α, CCL3), MIP-1β (CCL4), platelet-derived growth 
factor (PDGF-bb), regulated upon activation, normal T-cell expressed and secreted (RANTES, CCL5), 
tumor necrosis factor (TNF)-α, and vascular endothelial growth factor (VEGF). As controls, vitreous 
fluids collected in a similar way from 23 eyes of patients with noninflammatory vitreoretinal diseases 
such as epiretinal membrane (ERM) or macular hole were used. Statistical analyses were performed by 
comparing each patient’s data of the intravitreal substances to either 95 or 99% confidence interval for 
each control value. 
Case Reports 
Case 1 
The patient was a 27-year-old woman who noticed decreased vision in the left eye in January 2006 
and visited an ophthalmologist, who identified iridocyclitis and cataract and then referred her to our 
clinic. No family history or past illness was considered to have contributed to the condition. 
At the first consultation, best-corrected visual acuity was 1.5 in her right eye (OD) and hand motion 
in her left eye (OS). Intraocular pressure was 15 mm Hg OD and 12 mm Hg OS. No abnormal findings 
were observed in the right eye. In the left eye, keratic precipitates, mild iridocyclitis, and a posterior 
subcapsular cataract were observed. The iris of the left eye was lighter in color than that of the right eye, 
demonstrating heterochromia. Moreover, the left eye displayed iris nodules. As for the anterior chamber 
angle, peripheral anterior synechia was observed in the left eye, but no obvious angle neovascularization 
was seen. Details of the retina could not be visualized due to vitreous opacity. No active vitreous 
inflammatory reaction was observed. Based on these findings, the patient was diagnosed with FHI 
associated with cataract and vitreous opacity in the left eye, for which combined vitrectomy and cataract 
surgery were planned. 
PEA, PPV and IOL implantation were performed in April 2006. For IOL implantation, an acrylic 
IOL was inserted into the capsular bag. Amsler’s sign with a slight hemorrhage was observed in the 
anterior chamber angle of the opposite side at the time of paracentesis, immediately after the start of 
surgery. At the time of the vitrectomy, the vitreous body and retina were found to adhere in some parts. 
Surgery was completed without any complication. 
Visual acuity in the left eye was increased early after surgery, while intraocular pressure was normal 
at 18 mm Hg and inflammation in the anterior chamber was mild under topical instillation of 0.1% 
fluorometholone. The retina showed no abnormalities. Intraocular pressure increased to 30 mm Hg OS 
at 16 days after surgery, but was lowered by instillation of β-blocker. Steroid instillation was suspended 
at about 1 month after surgery. However, at 2 months after surgery, pressure elevated again to 36 mm 
Hg OS. Accordingly, topical instillation of carbonic anhydrase inhibitor was added, since then 
intraocular pressure has been favorably maintained at 15 mm Hg. Cellular precipitates on the surface of 
the IOL as well as an aftercataract began to develop rapidly in the left eye (fig. 1). Visual acuity was not 
restored by YAG laser capsulotomy of the posterior capsule, due to heavy precipitation on the IOL 
surface, and visual acuity dropped to 0.5. Administration of topical 0.1% fluorometholone was resumed 
at 3 months after surgery. Acuity in the left eye recovered to 1.2 until 5 months after surgery, as the 
precipitates on the IOL disappeared. 
Since that time, the transparency of the IOL surface has been maintained and no elevation of 
intraocular pressure has been seen. As of 3 years after surgery, the patient has a visual acuity of 1.5 and 
intraocular pressure of 16 mm Hg in the left eye without any treatment.  
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Case 2 
The patient was a 47-year-old woman with heterochromia, iridocyclitis, mild cataract, and vitreous 
opacity in the left eye since 2002. FHI was diagnosed. Visual acuity had been maintained at 1.0 OS, but 
dropped to 0.4 in 2004 along with the progression of posterior subcapsular cataract, which subsequently 
developed to mature cataract by 2006. Corrected visual acuity was 1.2 OD and hand motion OS. 
Intraocular pressures were 16 mm Hg OD and 14 mm Hg OS. No abnormalities were identified in the 
right eye. In the left eye, keratic precipitates and mild iridocyclitis were observed. The left ocular fundus 
could not be visualized due to mature cataract. Iris atrophy and Koeppe nodules were observed in the 
iris of the left eye. No abnormal findings were seen for the chamber angle. No laboratory data indicated 
other granulomatous uveitis such as sarcoidosis or Harada disease. 
PPV combined with PEA and IOL (acrylic IOL) implantation was performed in June 2006. Although 
opacity was found in the vitreous body, only lattice degeneration was seen in the retina. Unlike case 1, 
Amsler’s sign was not seen during surgery. Postoperative inflammatory response was mild, visual acuity 
was 1.0 and intraocular pressure was 18 mm Hg OS after surgery. However, intraocular pressure 
increased to 29 mm Hg by 14 days after surgery, then lowered to 16 mm Hg with the use of β-blocker 
eye drops. Although 0.1% fluorometholone administration was continued after surgery, white round 
precipitates started to form during the first postoperative month on the surface of the IOL, similar to 
those seen in Case 1 (fig. 2). Later, visual acuity was reduced in the left eye to 0.5 because of 
aftercataract, which was treated by YAG laser capsulotomy. Topical 0.1% fluorometholone instillation 
was continued until 2 years postoperatively. Visual acuity has remained at 1.2 OS and intraocular 
pressure has been maintained at 10 mm Hg without any eye drops. 
Results 
The concentrations of cytokines, chemokines and growth factors in vitreous fluid 
samples taken from Case 1 and 2 are summarized in table 1. In comparison to the control 
group, the levels of IL-1ra (p < 0.01, 0.05, respectively), IL-5 (p < 0.01), IL-6 (p < 0.01), IL-
8 (CXCL8, p < 0.01), IL-10 (p < 0.01), IL-13 (p < 0.01, 0.05, respectively), IP-10 (CXCL10, 
p < 0.01), MCP-1 (CCL2, p < 0.01), MIP-1α (CCL3, p < 0.05), MIP-1β (CCL4, p < 0.01), 
PDGF-bb (p < 0.01) and RANTES (CCL5, p < 0.01, 0.05, respectively) were significantly 
increased in the vitreous fluid of both FHI patients compared to those of patients with 
ERM. In addition, IL-2 (Case 2, p < 0.05), IL-12 (Case 2, p < 0.05), IL-17 (Case 2, p < 
0.05), G-CSF (Case 2, p < 0.05), IFN-γ (Case 1, p < 0.05), and VEGF (Case 1, p < 0.01) 
were significantly increased in only 1 patient and did not appear of any significance in the 
other patient (table 1). Conversely, IL-1β, IL-4, IL-7, IL-9, IL-15, eotaxin (CCL11), b-FGF, 
TNF-α and GM-CSF did not show any significant differences versus control samples.  
Discussion 
Iridocyclitis induced by FHI is characterized by mild inflammation of the anterior 
chamber, inflammation that does not become drastically aggravated, and an absence of 
peripheral anterior synechia, and is not curable by steroid therapy [18]. Moreover, steroid 
eye drops are not recommended to be administered to FHI patients over a long period, 
because of the possibility of glaucoma induced by FHI [3]. 
FHI-induced cataracts generally start with posterior subcapsular opacity, then quickly 
progress at some points [3]. In the present cases, cataracts progressed rapidly at a certain 
stage. Cataract surgery for FHI reportedly does not present unusual problems during the 
procedure, and postoperative inflammation is mild while the postoperative course is 
usually favorable [3–7]. In contrast, Javadi et al. [6] reported that the cause of poor vision 
in patients with postoperative visual acuity lower than 20/20 was vitreous opacity. 
Furthermore, Waters et al. [8] reported that vitrectomy for vitreous opacity was effective  
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for visual improvement in all cases analyzed, while cataracts were noted to progress at an 
early stage after the surgery. In view of these findings, benefits of combined vitrectomy 
and cataract surgery in FHI patients have been anticipated. Although Scott et al. [11] also 
noted that the results of pars plana lensectomy and PPV without IOL implantation were 
favorable, combined vitrectomy and cataract surgery with IOL implantation has rarely 
been reported. 
In the present cases, combined vitrectomy and cataract surgery was chosen, as severe 
vitreous opacity and cataracts were associated. Although intense inflammatory responses 
are frequently observed after combined vitrectomy and cataract surgery for other types of 
uveitis, postoperative inflammatory responses were relatively mild in FHI, at least during 
the early postoperative period. In our patients, however, round precipitates began to 
develop abundantly on the surface of the IOL from about 2 weeks to 1 month after 
surgery, while postoperative inflammation was mild. The precipitates disappeared within 
a few months after administering steroid eye drops. Javadi et al. [6] reported deposition 
on the IOL in 26.8% of the examined FHI cases. Agrawal et al. [5] reported that 
precipitates were formed on the IOL surface after cataract surgery for FHI and that visual 
impairment resulted, for which the use of steroid eye drops after surgery was 
recommended. Also, the elevation of intraocular pressure commonly observed in our 
patients could be controlled by topical instillation of β-blockers and carbonic anhydrase 
inhibitors.  
Previous studies have investigated the intraocular concentrations of multiple cytokines, 
chemokines and growth factors in patients with uveitis, noting that IL-6, IL-8, IL-10, IL-
12, IP-10, MCP-1, RANTES, MIP-1α, MIP-1β, and IFN-γ are present at high 
concentrations in aqueous humor [16, 19, 20]. Also, Banerjee et al. [17] reported 
cytokines, chemokines and growth factors in the vitreous fluid of various vitreoretinal 
diseases and showed that IL-6, MCP-1 and IL-8 were increased, while MIP-1α, MIP-1β, 
RANTES, eotaxin and IL-8 were not elevated in the vitreous fluid from patients with 
chronic uveitis. The levels of cytokines such as IFN-γ and chemokines such as RANTES, 
IP-10, MCP-1, and MIP-1α were also reportedly elevated in experimental autoimmune 
uveitis (EAU) mice [18, 21, 22]. In the present study, IL-1ra, IL-5, IL-6, IL-8, IL-10, IL-13, 
IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-bb and RANTES were shown to increase in 
vitreous fluid at significantly high concentrations in both patients with FHI. However, 
IFN-γ was only slightly elevated in just 1 patient (p < 0.05). This result may indicate that 
FHI does not have an autoimmune nature, unlike EAU. In addition, most chemokines 
examined in the present study were increased in the vitreous fluid. Because MIP-1, MCP-
1 and IP-10 play a role in the initial recruitment of inflammatory cells into the eye and IL-
8 activates and attracts neutrophiles [16]. Increased levels of these chemokines in the 
vitreous fluid may suggest that inflammatory reaction can be easily initiated using the 
vitreous cavity in our patients. Cellular precipitation on the IOL surface in the early 
postoperative period can be partially explained by the increased concentrations of these 
chemokines. Also, it should be noted that topical instillation of steroid eye drops is 
effective to treat cellular precipitation on the IOL. As for growth factors, the 
concentration of VEGF was elevated in Case 1 but not in Case 2. This result may explain 
the phenomenon that Amsler’s sign occurred only in Case 1, because neovascularization 
might have been induced in the chamber angle by an increased concentration of VEGF, 
although it was not observed by a preoperative gonioscopic examination. 
In conclusion, the present results suggest: first that various kinds of inflammatory 
cytokines and chemokines are elevated in the vitreous fluid of patients with FHI, second 
that postoperative inflammatory reactions may be related to these increased levels of  
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cytokines and chemokines, and third that topical instillation of steroid eye drops is 
effective to control postoperative inflammation and cellular precipitates on the IOL 
surface. Attention is also required in case of elevation of intraocular pressure during the 
early postoperative period. 
 
Table 1. Intravitreous concentrations of cytokines, chemokines and growth factors in Fuchs 
heterochromic iridocyclitis 
  0.Control Case  1  0Case2 
IL-1β  0.028.28±20.79  .000,57.5  000066 
IL-1ra  0.044.30±29.04  000242**  000112* 
IL-2  0.039.28±19.70  000061  000125* 
IL-4  0.053.33±41.19  000111  000154 
IL-5  0.016.26±13.59  .00,247.5**  000250** 
IL-6  0.188.24±167.78  0,2,111.5**  0.1,874** 
IL-7  0.051.83±37.58  000072  000074 
IL-8 (CXCL8)  0.193.61±164.04  .04,118**  0.1,773** 
IL-9  0.251.43±172.11  .00,494.5  000529 
IL-10  0.030.22±22.64  000874**  000483** 
IL-12  0.033.89±23.94  000064  000082* 
IL-13  0.024.98±21.14  000084*  .00,120.5** 
IL-15 1,121.89±282.14  0.1,101  0,1,471.5 
IL-17  .0154.52±117.99  .00,290.5  0.0,445.5* 
IP-10 (CXCL10)  1,166.39±1,589.52  .30,633**  .32,050** 
Eotaxin (CCL10)  00.44.41±34.54  000079  000097 
b-FGF  .0395.91±276.74  000576  000775 
G-CSF  .0037.76±27.90  000089  000113* 
IFN-γ  .0031.35±24.16  000085*  000079 
MCP-1 (CCL2)  4,167.85±3,503.73  .16,050**  .30,094** 
MIP-1α (CCL3)  .0041.98±32.35  000110*  000145* 
MIP-1β (CCL4)  .0358.02±336.57  0,2,583.5**  0,3,940.5** 
PDGF-bb  .0035.30±29.48  0.0,126.5**  000158** 
RANTES (CCL5)  .0171.93±289.71  .04,927**  0.1,032* 
TNF-α  .0158.11±106.52  000274  .00,268.5 
VEGF  .0215.17±201.52  0,1,068.5**  0.0,415.5 
GM-CSF  .0415.78±318.96  000689  000731 
All values are expressed in picogram/milliliter. * p < 0.05; ** p < 0.01. 
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Fig. 1. Case 1. Left eye at 2 months after surgery. Precipitates were formed on the IOL surface (arrow). 
 
 
 
Fig. 2. Case 2. Left eye at 1 month after surgery. Precipitates were formed on the IOL surface. 
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